Company Overview
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.05.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -64.19% |
| 6 Months: | - |
| 3 Months: | -69.35% |
| 1 Month: | -42.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)29.27 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 72.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CNXU Conexeu Sciences Inc. PHARMA | 4.68 | -13.76 | $125.23M | 0.00% | -53.84% | -53.36% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2025 | Apr 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 332.72K | 456.06K | 1.72M | 2.38M |
| Operating Income | -332.72K | -456.06K | -1.72M | -2.38M |
| EBITDA | -285.89K | -453.27K | -1.71M | -2.29M |
| Interest Expense | 3.61K | 1.38K | 0 | 0 |
| Pretax Income | -290.06K | -458.05K | -1.72M | -2.30M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -290.06K | -458.05K | -1.72M | -2.30M |
| Diluted EPS | -0.01 | -0.02 | -0.08 | -0.11 |
| R&D Expense | - | 42.47K | - | 66.61K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2024 | Oct 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 643.04K | 3.96M |
| Operating Income | -643.04K | -3.96M |
| EBITDA | -455.36K | -3.90M |
| Interest Expense | 16.50K | 4.95K |
| Pretax Income | -471.87K | -3.92M |
| Tax Provision | 0 | 0 |
| Net Income | -471.87K | -3.92M |
| Diluted EPS | -0.02 | -0.19 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2024 | Oct 2025 |
|---|---|---|
| Total Assets | 533.94K | 7.69M |
| Current Assets | 347.24K | 7.46M |
| Cash & Equivalents | 314.62K | 4.81M |
| Inventory | - | - |
| Receivables | 0 | 2.07M |
| Total Liabilities | 438.98K | 336.02K |
| Current Liabilities | 340.86K | 336.02K |
| Long Term Debt | 98.12K | - |
| Total Debt | 98.12K | - |
| Total Equity | 94.96K | 7.35M |
| Shares Outstanding | 20.92M | 20.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2024 | Oct 2025 |
|---|---|---|
| Operating Cash Flow | -225.44K | -1.67M |
| Investing Cash Flow | 0 | -89.99K |
| Financing Cash Flow | 534.64K | 6.28M |
| Capital Expenditure | - | -18.67K |
| Free Cash Flow | -225.44K | -1.69M |
| Net Change in Cash | 309.20K | 4.52M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2024 | Oct 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -496.9% | -53.4% |
| ROCE % | -333.0% | -53.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.04% | 12.26K | $60.83K |
| 2 | Citigroup Inc. | 0.02% | 5.22K | $25.89K |
| 3 | Morgan Stanley | 0.02% | 5.87K | $29.12K |
| 4 | Hollencrest Capital Management | - | 1.00K | $4.96K |
| 5 | Royal Bank of Canada | - | 887 | $4.40K |
| 6 | Jones Financial Companies, L.L.L.P. | - | 100 | $496 |
| 7 | Osaic Holdings Inc. | - | 100 | $496 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNXU
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE11bkRPX3EtVzlVT2VhT3lET3lWVnNaeGdtaGQxRlBxNTFmdmV6MjZEYk9qekhfZ2xFMS15c2lPYkJqc2tqci01Ti02MFNUT3po?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
$CNXU stock is down 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOZV9MSHJMdTZudkItT0FKai1uYzZpSUpGUWJ4S014TzcwZVNDUWJ3WTNkTVFEUTJfUE51bXFSMTBlSUNObHdtZXhLRXNreXRnejFtZzV2aEk1U2RiQk5mR3FZQ0JPdWlwRDRJZWYxVnV1ZENmSzhNOU1qOTZiNUY3a194RDhGX3c1eGQxZm…
Investment fund caps Conexeu Sciences (CNXU) stake below 10% - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQVEhJOXkyeXZtNl9vTThMbU5DTlFDY1R2QXZxemdzNGEtbkU4T2VWWW9IczAxYnlydlRNNUM4NjlIeXJUbjV5Szhqb0hfVmhFRUlrVmY4aUpkWjB3U1ViTXY0XzlZc29XVG9aRGYtV2pGZXhJeUJHSnloMFdYVTc2OFEwSmkzY2o5SFVnbj…
Conexeu Sciences (NASDAQ:CNXU) Shares Down 5.2% - Here's What Happened - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRlZMQUhlYkdpVFNWcW12TUdOcHRkQkhTV1lVb2NyRjhLUzgtRER5V3NSNndGeFlJcU0yQklBWEkyS3pQb0NKLWdQZ19tQ2EtTmowRkNHeGJBYVN3OG53SUtlaHI1VUVvQk5RYkRpcUpuc1hkVnAxd3lBM1ozazlBZzEwb2liV002d3p0Qj…
Conexeu Sciences (CNXU) Stock Could Be 47.6% Undervalued After FDA Prep And Leadership Moves - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOWE0tU3h6dVBGdlNxaG1tN29PWFB4dDJQMmpmc01fWFY2NHgxVWlPeWNtSUZ1Wl82Wi1pRXFvNUF2c19zV3RRbkJEb2JOQ3NtdGQxOVY2NHdFc3JoTUZjcU1mdzM0aTJuVWRwLWhYQVhBenNLNm5NZkZXR05MNjB0YTBGY1N3SnFGNUl5R1…
CNXU Stock Price and Chart — NASDAQ:CNXU - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1MSWpSUkdOeVNWYzNIZ0NtSVdfT1h2andRV2tXN25VMXl6aHl2dUpLZVo4STlvOEZQcWVPTEh5TFBvS19abGY2NTBhYjFRLUhXeVg0VC1FS19abHY3?oc=5" target="_blank">CNXU Stock Price and Chart — NASDAQ:CNXU</a…
CNXU — Frequently Asked Questions
What is the current share price of Conexeu Sciences Inc. (CNXU)?
As of 2026-09-19 21:16 PDT, Conexeu Sciences Inc. (CNXU) trades at $4.68 on NasdaqCM. Its 52-week range is $4.68 to $16.85.
What is the market capitalisation of CNXU?
Conexeu Sciences Inc. (CNXU) has a market capitalisation of $125.23M on NasdaqCM.
What is the P/E ratio of CNXU?
CNXU trades at a trailing price-to-earnings (P/E) ratio of -13.76. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 12.97.
What is the return on equity (ROE) of CNXU?
CNXU has a return on equity (ROE) of -53.36%. Its return on capital employed (ROCE) is -53.84%.
Is CNXU a good stock to buy?
This page provides a data-driven analysis of Conexeu Sciences Inc. (CNXU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.